Skip to content
Medicamen Biotech logo

Medicamen Biotech

MEDICAMEQ NSE
₹263.15 +1.00 (+0.38%)
P/E
32.93
View as Markdown
MCP
Close 4 Nov 2026 ₹263.15 −136.30 −34.1% 1Y
Start ₹399.45

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
5.82%
Debt to Equity
0.18
EPS (TTM)
₹7.99
Book Value
₹208.66
Market Cap
—
P/E (TTM)
32.93
P/B
1.26
ROE
3.95%
Dividend Yield
0.38%
EBITDA
₹22.70 Cr
52W High
₹447.65
52W Low
₹212.40
Day Range
₹254.00 – ₹267.80
Volume
10,373

Peer Comparison

Healthcare › Pharmaceuticals

Medicamen Biotech peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Medicamen Biotech (this company)
₹263.1532.93₹350 Cr1.260.38%3.95%5.82%₹203 Cr₹10 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.48%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

44 Weak

Data confidence 100/100

surveillance:ESM1

Category scores

Quality
35
Poor
Returns, margins, earnings quality 22% weight
Valuation
40
Weak
Cheap vs sector & own history 24% weight
Growth
72
Strong
Sales & profit trajectory 9% weight
Financial Health
59
Good
Solvency, leverage, coverage 9% weight
Momentum
43
Weak
Trend strength, vol-adjusted 12% weight
Ownership
57
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • The company has delivered a poor sales growth of 11.9% over past five years.
  • Company has a low return on equity of 4.23% over last 3 years.
  • Dividend payout has been low at 14.5% of profits over last 3 years
  • Company has high debtors of 151 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1162
OscillatorsBearish261
Moving AveragesStrong Bearish901

Key readings

RSI (14)
41.26
Neutral
MACD (12,26,9)
−10.20
Bearish
SMA (50)
287.74
Bearish
SMA (200)
276.32
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+11.87%
3Y+11.98%
1Y+21.47%
TTM+24.67%

Net profit

Net profit growth by window
5Y−3.58%
3Y−12.64%
1Y+42.86%
TTM+37.81%

Operating cash flow

Operating cash flow growth by window
5YTurned negative
3YOutflow widened by ₹27 Cr
1YOutflow widened by ₹25 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−7.09 pp
3Y−6.41 pp
1Y+2.02 pp
TTM+0.28 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹123 Cr
Mar 2020₹125 Cr
Mar 2021₹113 Cr
Mar 2022₹115 Cr
Mar 2023₹141 Cr
Mar 2024₹179 Cr
Mar 2025₹163 Cr
Mar 2026₹198 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹12.00 Cr
Mar 2020₹13.00 Cr
Mar 2021₹12.00 Cr
Mar 2022₹15.00 Cr
Mar 2023₹15.00 Cr
Mar 2024₹9.00 Cr
Mar 2025₹7.00 Cr
Mar 2026₹10.00 Cr

Quarterly Results

₹ Cr
MEDICAMEQ quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
41.94
43.54
46.5
47.32
43.05
44.74
45.14
29.61
43.04
47.17
46.91
60.65
47.9
Expenses
34.99
38.89
41.6
41.57
39.6
39.43
38.43
31.22
38.43
42.01
42.53
55.22
43.57
Operating Profit
6.95
4.65
4.9
5.75
3.45
5.31
6.71
−1.61
4.61
5.16
4.38
5.43
4.33
OPM %
16.57%
10.68%
10.54%
12.15%
8.01%
11.87%
14.86%
−5.44%
10.71%
10.94%
9.34%
8.95%
9.04%
Other Income
0.38
0.55
0.83
0.57
0.59
0.29
0.14
5.23
0.47
0.37
0.53
1.74
0.86
Interest
0.96
0.91
0.65
1.89
0.71
1.04
0.76
0.65
1.15
0.99
0.97
0.38
0.83
Depreciation
1.69
1.82
1.8
1.77
1.77
2.61
2.21
0.48
1.8
1.86
1.83
1.73
1.79
PBT
4.68
2.46
3.27
2.66
1.56
1.96
3.88
2.49
2.13
2.68
2.11
5.06
2.57
Tax %
15.81%
39.68%
38.11%
22.93%
48.72%
53.85%
24.74%
25.3%
24.88%
21.27%
22.27%
12.06%
28.4%
Net Profit
3.95
1.48
2.03
2.04
0.8
0.9
2.92
1.87
1.6
2.11
1.64
4.45
1.85
EPS (₹)
3.3
1.19
1.9
1.68
1.06
1.15
2.73
1.9
1.59
1.97
1.61
2.85
1.56

Profit & Loss

₹ Cr
MEDICAMEQ profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
123
125
113
115
141
179
163
198
203
Expenses
105
106
93
91
117
156
148
177
183
Operating Profit
17
20
20
24
24
24
14
21
19
OPM %
14%
16%
17%
21%
17%
13%
9%
10%
10%
Other Income
4
2
1
2
2
2
6
3
4
Interest
1
1
2
2
3
6
4
5
3
Depreciation
2
2
3
6
6
7
7
7
7
PBT
18
18
16
18
17
13
10
12
12
Tax %
31%
26%
26%
18%
14%
27%
34%
18%
—
Net Profit
12
13
12
15
15
9
7
10
10
EPS (₹)
10.28
10.88
9.93
12.2
11.73
8.6
5.59
7.11
7.99
Div. Payout %
10%
5%
10%
8%
9%
12%
18%
14%
—

Balance Sheet

₹ Cr
MEDICAMEQ balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
12
12
12
12
13
13
13
14
Reserves
75
109
121
134
181
194
200
262
Borrowings
12
11
19
26
26
31
34
49
Other Liabilities
38
49
42
53
59
56
50
47
Total Liabilities
137
181
194
226
279
295
297
372
Fixed Assets
24
34
90
92
93
92
87
85
CWIP
15
40
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
Other Assets
97
107
104
133
186
203
210
287
Total Assets
137
181
194
226
279
295
297
372

Cash Flow

₹ Cr
MEDICAMEQ cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4
13
13
4
−6
−7
−8
−33
Investing
−15
−37
−18
−8
−6
−6
−1
−3
Financing
−4
19
6
4
29
6
−1
64
Net Cash Flow
−14
−5
1
0
17
−6
−11
28
Free Cash Flow
−11
−25
−5
−4
−13
−13
−10
−38
CFO/OP
48
88
88
30
−13
−16
−47
−150

Ratios

MEDICAMEQ financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
129
145
170
200
169
112
155
151
Inventory Days
67
78
27
188
228
234
268
251
Days Payable
134
173
169
302
241
154
184
144
Cash Conversion Cycle
62
51
28
86
156
193
239
259
Working Capital Days
116
130
126
147
156
123
186
193
ROCE %
—
16%
13%
12%
10%
8%
6%
6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Medicamen Biotech insights

70 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 53.03%
  • Promoters 42.57%
  • FIIs 4.35%
  • Government 0.05%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Concall · Nov 2024
    PPT
  • Concall · Dec 2021
    PPT
  • Q2 FY21 concall · Nov 2020
    PPT
  • Q1 FY21 concall · Aug 2020
    PPT
  • Concall · Jun 2020
    PPT

Frequently Asked Questions about Medicamen Biotech

What does Medicamen Biotech Ltd do?
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations
Where is Medicamen Biotech Ltd (MEDICAMEQ) listed?
Medicamen Biotech Ltd trades as MEDICAMEQ on the NSE and under code 531146 on the BSE.
Which sector does Medicamen Biotech Ltd belong to?
Medicamen Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Medicamen Biotech Ltd?
Medicamen Biotech Ltd trades at a PE ratio of 32.93 as of 4 Nov 2026, on earnings per share of ₹7.99, against a book value of ₹208.66 per share.
What is the 52-week high and low of Medicamen Biotech Ltd?
Over the last 52 weeks Medicamen Biotech Ltd has traded between ₹212.4 and ₹447.65 as of 4 Nov 2026.
Does Medicamen Biotech Ltd pay dividends?
Medicamen Biotech Ltd has a dividend yield of 0.38%.
What is the Return on Equity (ROE) of Medicamen Biotech Ltd?
Medicamen Biotech Ltd reported a return on equity of 3.95%. Its debt-to-equity ratio is 0.18.

Company Information

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations

Website medicamen.com
CEO Mr. Rajesh Madan B. Pharma
Employees 376
Listed 12 Jan 2005
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDICAMEQ.md for Medicamen Biotech Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month